Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,744 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
Armstrong AW, Warren RB, Zhong Y, Zhuo J, Cichewicz A, Kadambi A, Junqueira D, Westley T, Kisa R, Daamen C, Augustin M. Armstrong AW, et al. Among authors: zhong y. Dermatol Ther (Heidelb). 2023 Nov;13(11):2839-2857. doi: 10.1007/s13555-023-01034-7. Epub 2023 Oct 6. Dermatol Ther (Heidelb). 2023. PMID: 37801281 Free PMC article.
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
Armstrong AW, Augustin M, Beaumont JL, Pham TP, Hudgens S, Gordon KB, Zhuo J, Becker B, Zhong Y, Kisa RM, Banerjee S, Papp KA. Armstrong AW, et al. Among authors: zhong y. Dermatol Ther (Heidelb). 2024 Aug;14(8):2235-2248. doi: 10.1007/s13555-024-01224-x. Epub 2024 Jul 30. Dermatol Ther (Heidelb). 2024. PMID: 39080153 Free PMC article.
Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis.
Tsai TF, Tada Y, Kung C, Zhong Y, Cichewicz A, Borkowska K, Westley T, Kisa RM, Huang YH, Gao XH, Jo SJ, Armstrong AW. Tsai TF, et al. Among authors: zhong y. J Dermatol. 2024 Dec;51(12):1559-1571. doi: 10.1111/1346-8138.17448. Epub 2024 Nov 11. J Dermatol. 2024. PMID: 39526612 Free PMC article.
Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study.
Tada Y, Kim H, Spanopoulos D, Habiro K, Tsuritani K, Yamada Y, Mandal A, Zhong Y, Hikichi Y. Tada Y, et al. Among authors: zhong y. J Dermatol. 2022 Nov;49(11):1106-1117. doi: 10.1111/1346-8138.16543. Epub 2022 Aug 10. J Dermatol. 2022. PMID: 35946343 Free PMC article.
Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America.
Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. Strober B, et al. Among authors: zhong y. J Psoriasis Psoriatic Arthritis. 2024 Nov 21:24755303241302070. doi: 10.1177/24755303241302070. Online ahead of print. J Psoriasis Psoriatic Arthritis. 2024. PMID: 39583219 Free PMC article.
10,744 results
You have reached the last available page of results. Please see the User Guide for more information.